PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment
A PD-L1xVδ2 bsTCE was generated that acts as PD-1/PD-L1 immune checkpoint inhibitor, enhances Vγ9Vδ2-T cell activation, infiltration and tumor lysis and reshapes the tumor microenvironment towards a more proinflammatory state. By targeting both PD-L1 expressing tumor and myeloid cells, it addresses key challenges of current therapies and thereby offers a promising novel therapeutic strategy.
Authors
- Marko Popović (ORCID: https://orcid.org/0000-0003-2360-3982)
- Małgorzata Roos (ORCID: https://orcid.org/0000-0001-9878-6969)
- Hans van Vliet (ORCID: https://orcid.org/0000-0001-7846-8613)
- Myrthe Veth (ORCID: https://orcid.org/0009-0006-3551-2243)
- Tanja D. de Gruijl (ORCID: https://orcid.org/0000-0003-1464-8978)
- Lisa A. King (ORCID: https://orcid.org/0009-0001-8705-150X)
- George L. Scheffer
Institutions
- Lava Therapeutics (Netherlands) (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012255
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05